One or two fractions of 12 Gy delivered to murine breast carcinoma together with an anti-CTLA4 antibody led to improved survival in mice when compared with RT or anti-CTLA4 therapy alone [49]. This evidence concerns the gene CTLA4 and breast carcinoma.